BioXcel Therapeutics (BTAI) Competitors $1.79 -0.20 (-10.05%) Closing price 03:59 PM EasternExtended Trading$1.80 +0.01 (+0.84%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BTAI vs. KZR, PULM, DYAI, MRNS, ALXO, BCAB, ALLK, ONCY, FGEN, and VORShould you be buying BioXcel Therapeutics stock or one of its competitors? The main competitors of BioXcel Therapeutics include Kezar Life Sciences (KZR), Pulmatrix (PULM), Dyadic International (DYAI), Marinus Pharmaceuticals (MRNS), ALX Oncology (ALXO), BioAtla (BCAB), Allakos (ALLK), Oncolytics Biotech (ONCY), FibroGen (FGEN), and Vor Biopharma (VOR). These companies are all part of the "pharmaceutical products" industry. BioXcel Therapeutics vs. Kezar Life Sciences Pulmatrix Dyadic International Marinus Pharmaceuticals ALX Oncology BioAtla Allakos Oncolytics Biotech FibroGen Vor Biopharma BioXcel Therapeutics (NASDAQ:BTAI) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, community ranking, dividends, profitability and media sentiment. Is BTAI or KZR more profitable? Kezar Life Sciences has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -3,119.33%. BioXcel Therapeutics' return on equity of 0.00% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets BioXcel Therapeutics-3,119.33% N/A -105.04% Kezar Life Sciences N/A -54.95%-46.11% Does the media refer more to BTAI or KZR? In the previous week, BioXcel Therapeutics had 2 more articles in the media than Kezar Life Sciences. MarketBeat recorded 3 mentions for BioXcel Therapeutics and 1 mentions for Kezar Life Sciences. Kezar Life Sciences' average media sentiment score of 1.89 beat BioXcel Therapeutics' score of 0.63 indicating that Kezar Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment BioXcel Therapeutics Positive Kezar Life Sciences Very Positive Does the MarketBeat Community believe in BTAI or KZR? BioXcel Therapeutics received 110 more outperform votes than Kezar Life Sciences when rated by MarketBeat users. Likewise, 67.49% of users gave BioXcel Therapeutics an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformBioXcel TherapeuticsOutperform Votes24767.49% Underperform Votes11932.51% Kezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% Which has stronger valuation & earnings, BTAI or KZR? Kezar Life Sciences has higher revenue and earnings than BioXcel Therapeutics. Kezar Life Sciences is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioXcel Therapeutics$1.85M5.85-$179.05M-$13.55-0.13Kezar Life Sciences$7M4.99-$101.87M-$10.82-0.44 Do insiders & institutionals believe in BTAI or KZR? 30.7% of BioXcel Therapeutics shares are held by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer BTAI or KZR? BioXcel Therapeutics presently has a consensus target price of $42.60, suggesting a potential upside of 2,279.89%. Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 726.19%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Kezar Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more volatility & risk, BTAI or KZR? BioXcel Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500. SummaryBioXcel Therapeutics beats Kezar Life Sciences on 11 of the 19 factors compared between the two stocks. Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BTAI vs. The Competition Export to ExcelMetricBioXcel TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.84M$6.84B$5.57B$8.60BDividend YieldN/A2.49%5.27%4.19%P/E Ratio-0.058.7927.2720.06Price / Sales5.85255.05409.23156.87Price / CashN/A65.8538.2534.64Price / Book-0.066.557.064.70Net Income-$179.05M$143.71M$3.23B$247.80M7 Day Performance16.99%3.76%2.69%2.17%1 Month Performance16.99%13.97%12.06%9.41%1 Year Performance-92.18%4.76%31.40%14.73% BioXcel Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BTAIBioXcel Therapeutics4.099 of 5 stars$1.79-10.1%$42.60+2,279.9%-91.4%$10.84M$1.85M-0.0590Gap UpKZRKezar Life Sciences4.6185 of 5 stars$4.37+4.5%$39.50+803.9%-34.9%$31.93M$7M-0.3360Positive NewsPULMPulmatrix0.8099 of 5 stars$8.58-4.5%N/A+333.3%$31.32M$1.92M-3.2520DYAIDyadic International2.154 of 5 stars$1.02-1.6%$6.00+488.2%-52.9%$30.69M$3.34M-4.437Positive NewsMRNSMarinus Pharmaceuticals1.9491 of 5 stars$0.55-0.2%$4.79+771.6%-64.3%$30.32M$30.99M-0.22110News CoverageALXOALX Oncology2.9367 of 5 stars$0.56+15.1%$3.30+490.7%-93.8%$29.83MN/A-0.1940News CoverageAnalyst RevisionGap UpBCABBioAtla2.7651 of 5 stars$0.51+24.7%$5.00+880.4%-67.5%$29.79M$11M-0.3060Gap UpHigh Trading VolumeALLKAllakos3.9295 of 5 stars$0.33flat$2.00+507.7%N/A$29.74MN/A-0.16190ONCYOncolytics Biotech1.5876 of 5 stars$0.34+1.2%$4.33+1,159.7%-58.1%$29.73MN/A-1.2730News CoverageGap UpFGENFibroGen4.1917 of 5 stars$0.29+2.2%$10.00+3,303.7%-72.6%$29.69M$7.00M-0.24570VORVor Biopharma3.3734 of 5 stars$0.23+17.2%$7.06+2,912.0%-82.3%$29.28MN/A-0.14140High Trading Volume Related Companies and Tools Related Companies Kezar Life Sciences Alternatives Pulmatrix Alternatives Dyadic International Alternatives Marinus Pharmaceuticals Alternatives ALX Oncology Alternatives BioAtla Alternatives Allakos Alternatives Oncolytics Biotech Alternatives FibroGen Alternatives Vor Biopharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BTAI) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BTAI Stock Free BTAI Stock Alerts